How a microbial‑first CDMO turns complex nanoparticle concepts into clinical‑grade candidates TL;DRBiologic nanoparticles (including VLPs and engineered protein assemblies) offer precise antigen display, tunable valency, and new immune‑engagement mechanisms. A microbial‑first approach reduces cost and time while improving manufacturability. Below is a six‑stage playbook—from scoping to scale‑up—plus pitfalls to avoid, where VLPs fit now, and […]
Tag: VLP Vaccines
Plasmid DNA & mRNA Manufacturing: How a Microbial-First CDMO Unlocks the Next Wave of Biologics
At Mika Biologics, we build manufacturability by default. Microbes are our engine. Speed, quality, and scale are the outputs. Executive take Plasmid DNA & mRNA manufacturing now sits at the backbone of modern biologics—from genetic vaccines and in vivo gene editing to engineered cell therapies and next-generation immuno-oncology. Demand for fast, GMP-grade supply chains is […]
Endotoxin-Free Biologics: Preventing LPS at the Source
Biologics have transformed medicine. Monoclonal antibodies, cytokines, vaccines, enzymes, and nanoparticles are no longer niche—they dominate the global pharmaceutical pipeline and generate revenues in the hundreds of billions. Yet one microscopic adversary continues to sabotage this progress: endotoxins. Lipopolysaccharide (LPS), shed from Gram-negative bacteria, is the hidden saboteur of biologics manufacturing. At picogram levels, it […]
Engineered Probiotics: The Future of Living Medicines
Introduction: The Next Frontier in Biologics Imagine if medicines didn’t just flow through your bloodstream—they lived there, adapting moment by moment to your biology. That future is arriving quickly through engineered probiotics—living microbial therapies designed not only to treat symptoms but to heal, regulate, and enhance human health at its source. Unlike traditional biologics or […]
Microbial CDMOs: The Future of Biologics
Introduction: The Microbial CDMO Revolution Biopharma is at an inflection point, and microbial CDMOs are central to the shift. Biologics now drive growth across the industry, yet the manufacturing backbone—CDMOs—remains overwhelmingly built around mammalian cell systems. That legacy architecture is slow, expensive, and capacity-constrained just as demand accelerates. The model is cracking. Emerging modalities—cytokines, phage […]
The Rise of Microbial-First CDMOs: Why the Future of Biologics Belongs to Microbes
At Mika Biologics, we often describe our philosophy in three words: Microbial. Innovation. Beyond. To us, these words are not slogans—they are a strategic compass. They reflect a conviction that the next generation of biologics will not be built on the same foundations as the last. While mammalian expression systems have dominated the landscape for […]